The report "Global Duchenne Muscular Dystrophy Treatment Market By Therapeutic Approach and Treatment (Molecular-based Therapies (Mutation Suppression, and Exon Skipping), Steroid Therapy (Corticosteroids), Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Other Therapeutic Approaches and Treatment End Users), By End User (Hospitals/Clinics, Ambulatory Centers, and Other End Users), and Region - Global Forecast to 2029" Global Duchenne Muscular Dystrophy Treatment market is projected to grow from US $xx billion in 2019 to US$ XX billion by 2029. The rising burden of Duchenne muscular dystrophy (DMD) disease is the major factor driving the growth for the target market. The increasing prevalence of chronic diseases, such as cardiovascular and neurovascular diseases, and arthritis are the major factor boosting the growth for the target market. However, factor such as changing government regulations and norms restrain market growth.

Key Highlights:

• In April 2019 FibroGen a leading biopharmaceutical company receives orphan drug designation from the U.S. FDA for pamrevlumab for the treatment of Duchenne muscular dystrophy.

Key Market Insights from the report:        

The global Duchenne Muscular Dystrophy Treatment market accounted for US$ XX billion in 2019 and is projected to register a moderate CAGR of XX% over the forecast period. The market report has been segmented on the basis, By Therapeutic Approach and Treatment Type, End-User, and by a region.

• By Therapeutic Approach and Treatment Type global Duchenne Muscular Dystrophy Treatment market is classified into molecular-based therapies (mutation suppression, and exon skipping), steroid therapy (corticosteroids), nonsteroidal anti-inflammatory drugs (NSAIDs) and other therapeutic approaches and treatment end users.
• By End-User global Duchenne Muscular Dystrophy Treatment, the market is classified into hospitals/clinics, ambulatory centres, and other end users.
• By region, The Asia Pacific market is expected to show the highest CAGR owing to growing awareness about Duchenne muscular dystrophy and growing public and private health care insurance coverage. North America is expected to domination the market. Owing to product innovations, great healthcare expenditure, and support of government awareness programs.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Duchenne Muscular Dystrophy Treatment Market By Therapeutic Approach and Treatment (Molecular-based Therapies (Mutation Suppression, and Exon Skipping), Steroid Therapy (Corticosteroids), Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Other Therapeutic Approaches and Treatment End Users), By End User (Hospitals/Clinics, Ambulatory Centers, and Other End Users), and By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) - forecast till 2029

To know the upcoming trends and insights prevalent in this market, click the link below:

Links: https://prophecymarketinsights.com/market_insight/Global-Duchenne-Muscular-Dystrophy-Treatment-3969

The key players operating the global Duchenne Muscular Dystrophy Treatment market include BioMarin, Bristol-Myers Squibb Company, Fibrogen Inc., Eli Lilly and Company, Nobelpharma Co. Ltd, NS Pharma Inc., Pfizer Inc., PTC Therapeutics, Santhera Pharmaceuticals and Sarepta Therapeutics. The Key players in the market are focusing on mutual understanding. 

About Prophecy Market Insights

Prophecy Market Insights is a specialized market research, analytics, marketing and business strategy, and solutions company that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. Also, we help our client to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Sales

Prophecy Market Insights

Email- This email address is being protected from spambots. You need JavaScript enabled to view it.

Leading VTM kit manufacturers in India sold more than 50 million VTM Kits, becomes the largest supplier

Pathkits, one of the best VTM kit manufacturers in India, recently sold more than 50 million VTM (Viral Transport Medium) kits and becomes the largest supplier in India. Since COVID-19 drastically hit the nation, there’s been a huge demand among medical authorities and hospitals to have VTM kits to collect and transport viruses from one place to another. Although the cases are declining now, the demand is showing no signs of slowing down. 

The diagnosis of COVID-19 viral infection solely depends on the collection of proper specimens and proper care to protect the virus from getting spread into the environment to curb its activity. Pathkits clearly understood the situation and acted accordingly by manufacturing VTM kits to allow the safe transfer of viruses for diagnostic purposes. 

Viral Transport medium Kits (VTM Kits) are specially formulated equipment medium that is helpful in collection and transportation of viruses, ensuring the optimum viability of the sample is maintained. Made of Hanks’ Balanced Salt Solution and contain protective protein antibiotics, viral transport medium kits are designed with an aim to control microbial contamination and buffers for the effective control of pH.

The medium also contains a cryoprotectant that helps in preserving the virus if specimens are frozen for prolonged storage. These kits come with a flexible plastic shaft that helps to provide convenience to patients. For efficient collection and release of particulate matter, the plastic shaft is attached with soft nylon strands which help in increasing the sensitivity of serological and molecular detection assays. 

The unique formulation of the transport medium helps in preserving the viability of viruses for up to 3 days or 72 hours (at refrigerated temperatures). All the VTM kits strictly adhere to the CDC (Centers for Disease Control and Prevention) recommended guidelines for any viral specimen collection of virus including COVID-19. Even doctors claimed that the kit is valid against the pandemic SARS-Cov-2 from ICMR-NIV.

With state-of-the-art technology and immense experience, the company managed to manufacture viral transport medium kits that; 

• Inactivates the virus immediately, allows safe collection & transportation of COVID 19 specimen.
• Preserves and stabilizes the RNA at a higher temperature.
• Allows the safe handling of specimens to ensure the doctors and healthcare professionals are safe.  
• Comes with tube dimensions- 16mm X 100mm Media- 3 ml & 1.5 ml.

In addition to the sterile VTM kits, the company has also developed RNA isolation kits and RT-PCR kits. By using the enzyme Reverse Transcriptase (RT), the isolated and purified RNA is then converted to DNA, which is used to confirm whether the respective person is suffering from COVID-19 or not. 

To know more about their VTM kits and other associated solutions, simply visit https://pathkits.com/

About Pathkits: 

Pathkits is one of the best VTM kit manufacturers in India that has an extensive distribution network across India. They endeavor to stay ahead with a relentless drive that was set into motion since their inception. With the vision of their founders, doctors, healthcare professionals, partners, stakeholders, and customers, they continued to break the boundaries and thus, sold more than 50 million viral transport medium kits. Backed by the latest technologies and a team of medical professionals, the company has a sole mission to provide the highest quality of healthcare solutions to mankind. 

Media Contacts: 

Mobile No- (+91) 7303429198

Email Id: This email address is being protected from spambots. You need JavaScript enabled to view it.

Opening hours: Mon-Sat: 8 am to 8 pm

Collaboration agreement between Grenada and the Russian Direct Investment Fund (RDIF) allows for the initial distribution of 1 million doses of the Sputnik V COVID-19 vaccine for the Caribbean Community (CARICOM) region.

Moscow, Russia, March 24, 2021 -- The Government of Grenada represented by the Ministry of Health and the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, have announced a cooperation agreement designed to facilitate the registration and distribution of the Sputnik V coronavirus vaccine in Grenada and the Caribbean Community (CARICOM) region.

Sputnik V adenovirus vector vaccine was developed by Russia’s Gamaleya National Research Institute of Epidemiology and Microbiology for SARS-Cov-2 (COVID-19) (the “Vaccine”).

As part of the agreement, the parties agree to organize the initial supply of up to 1 million doses of the Vaccine (one dose to be deemed to comprise injections of Ad5 and Ad26) to the region under the authorisation from the RFID and the Institute. Grenada will serve as a local centralized distribution point in the region and undertake the logistics and regulatory approval for the Vaccine.

Derived from the human adenoviral vector-based platform, the Sputnik V vaccine uses two different vectors for the two shots of the vaccination. It provides immunity for longer than the vaccines with the same delivery mechanism for both shots.

The Sputnik V vaccine has been registered in more than 50 countries. Countries in North and South America, the Middle East, Europe, Asia, and Africa have made requests for more than 1.2 billion doses of the vaccine.

As of February 2021, vaccination with Sputnik V has started or is starting in more than 20 countries besides Russia, including Argentina, Hungary, Bolivia, Algeria, Montenegro, Paraguay, Venezuela, and others.

“We are pleased to partner with RDIF to bring the vaccine to The Caribbean Community. According to the data published in The Lancet medical journal, Sputnik V COVID-19 vaccine appears safe and effective,” commented Hon. Nickolas Steele, Minister for Health and Social Security of Grenada. “Sputnik V vaccine could provide a credible option in our fight against COVID-19 in Grenada and the CARICOM,” continued Hon. Nickolas Steele.

“The agreement between Grenada and the RDIF will help the CARICOM population obtain access to a coronavirus vaccine with an efficacy of almost 92% created using a proven and well-studied platform of human adenovirus vectors,” H.E. Oleg Firer, Ambassador Extraordinary and Plenipotentiary of Grenada added. “Grenada’s diplomatic mission in Moscow is the only fully accredited mission of CARICOM in the Russian Federation and is proud of its accomplishment to deliver vital medicine to the region.

About Embassy of Grenada:
Embassy of Grenada in Moscow, Russia is the diplomatic mission that represents Grenada in the Russian Federation and the Commonwealth of Independent States (CIS), protecting the interests of the Government and people of Grenada. Embassy of Grenada negotiates with the host governments and promotes friendly relations between Grenada, Russian Federation and the CIS member states, developing economic, cultural and scientific relations. The Embassy also provides Consular Services for Grenadian nationals and those wishing to visit or immigrate to Grenada. More information: https://grenadaembassy.ru.

About Russian Direct Investment Fund:
RDIF is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries and total more than $40 bn. Since the start of the COVID-19 pandemic RDIF has played a key role in fighting the virus in Russia. Working jointly with some of the world’s top institutional investors, we have selected and funded what we believe are the most promising COVID-19 testing systems, drugs and vaccines. RDIF supports the development of Russia’s COVID-19 vaccine by the Gamaleya Center and is investing in mass production of the vaccine by RDIF portfolio companies. More information: https://rdif.ru.

Contact:
Oleg Firer
Embassy Press Services
40 Povarskaya Street
Moscow, Russia 121069
+7-495-241-01-11
This email address is being protected from spambots. You need JavaScript enabled to view it.
http://grenadaembassy.ru

West Texas Bariatric, based in Lubbock, has become a licensee of the HMR weight loss program.

Lubbock, TX - USA | March 17, 2021 -- To some, bariatric surgery may seem like an easy way to achieve rapid weight loss. However, bariatric surgery patients still have to adapt to a healthy lifestyle and eat a low-calorie diet. Some patients fail at weight loss because they do not follow a diet low in calories in the long-term.

This West Texas bariatric surgery clinic addresses this problem through their clinic-based weight loss approach. West Texas Bariatric, based in Lubbock, has become a licensee of the HMR weight loss program.

The HMR weight loss program is a non-surgical, clinic-based diet regimen that has been named by U.S. News as one of their “best diets for fast weight loss” in 2020. It uses a radical approach that allows participants to eat as much as they wish, so long as they stick to a specific list of foods.

The way the HMR diet works is on a 3+2+5 system. 3+2+5 doesn’t sound very descriptive in itself, but it’s actually a very clever approach to one of the most common problems in weight loss: hunger. On the 3+2+5 system, a participant would consume 3 shakes known as HMR shakes, 2 HMR entree portions, and 5 services of fruits and vegetables.

Think those portions aren’t enough for the day? No problem, eat more food, so long as it’s an HMR-approved portion of food. HMR foods don’t just include fruits and vegetables: there are HMR pudding snacks and bars as well. This approach at weight loss aims to address two very common issues that people have when trying to lose weight: hunger and cravings.

By allowing as many portions of certain foods as the participant would like, nobody on the program has to worry about feeling hungry after they’ve hit a set limit on food consumption. And, by allowing participants to eat certain delicious low-calorie foods, they can satisfy cravings that they would otherwise give into if they were hungry.

West Texas Bariatric, a clinic specializing in procedures such as the gastric sleeve and gastric bypass in West Texas, now offers this program as a licensee as an alternative to bariatric surgery procedures.

“Our goal is to address this obesity epidemic that we’ve been dealing with for far too long,” says Dr. Travis Eggl, a board-certified bariatric surgeon at West Texas Bariatric. “We’re committed to providing the community with effective weight loss options, surgical and non-surgical. We provide HMR diets to those who do not qualify for bariatric surgery or those who would rather avoid going under the knife.”

West Texas Bariatric is a weight loss clinic based in Lubbock, TX that offers gastric bypass, sleeve gastrectomy, HMR diets, and other weight loss interventions. Visit them at https://westtexasbariatric.com.

Press & Media Contact:
West Texas Bariatrics at SWAT Surgical
3611 22nd Place,
Lubbock, TX 79410
+1 806-771-2222
https://westtexasbariatric.com